Premium
Long‐term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro : studies with primary tumour cells and LTBMC‐dependent cell lines
Author(s) -
Bloem Andries C.,
Lamme Tanja,
De Smet Martin,
Kok Henriette,
Vooijs Wim,
Wijdenes John,
Boom Saskia E.,
Lokhorst Henk M.
Publication year - 1998
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1998.00517.x
Subject(s) - stromal cell , bone marrow , in vitro , cell culture , cancer research , multiple myeloma , chemistry , pathology , immunology , medicine , biology , biochemistry , genetics
Long‐term bone marrow cultured stromal cells (LTBMC) produce IL‐6 after contact with tumour cells from multiple myeloma patients. We found that LTBMC could substitute for exogenous IL‐6 in the stimulation of bone marrow plasma cells from myeloma patients with active disease in short‐term cultures. In addition, tumour cells of some patients with inactive disease, which were unresponsive to exogenous IL‐6, were induced to IL‐6‐dependent growth after LTBMC co‐culture. To study the role of LTBMC in myeloma tumour growth in vitro , plasma cell lines UM‐2 and UM‐3 were selected. UM‐2 and UM‐3 grew in contact with LTBMC and proliferation was blocked by antibodies against IL‐6, IL‐6 receptor (IL‐6R, gp80, CD126) or the common signal transducing unit, gp130 (CD130). Culture with IL‐6 alone or combined with GM‐CSF resulted in cell death via apoptosis. The combination of IL‐6 with soluble gp80, however, maintained in vitro proliferation of UM‐2 and UM‐3 cells. These data imply that LTBMC regulate myeloma growth in vitro via production of IL‐6, possibly via induction of a functional IL‐6 receptor on the tumour cells.